Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $260.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by Evercore ISI from $220.00 to $260.00 in a research report released on Tuesday,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

A number of other brokerages have also recently commented on ASND. Oppenheimer reduced their price target on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th. JPMorgan Chase & Co. raised their price objective on Ascendis Pharma A/S from $167.00 to $168.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. UBS Group initiated coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a “buy” rating and a $196.00 price target on the stock. Stifel Nicolaus boosted their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $197.36.

Ascendis Pharma A/S Price Performance

ASND stock opened at $154.58 on Tuesday. The firm has a 50 day simple moving average of $134.09 and a two-hundred day simple moving average of $132.88. The stock has a market cap of $9.38 billion, a PE ratio of -21.77 and a beta of 0.64. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. On average, research analysts expect that Ascendis Pharma A/S will post -4.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ASND. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Ascendis Pharma A/S in the fourth quarter worth $28,000. Wilmington Savings Fund Society FSB purchased a new stake in Ascendis Pharma A/S in the third quarter worth about $30,000. Jones Financial Companies Lllp lifted its holdings in shares of Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 197 shares during the last quarter. Blue Trust Inc. boosted its position in shares of Ascendis Pharma A/S by 415.2% in the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 328 shares in the last quarter. Finally, Groupama Asset Managment bought a new position in Ascendis Pharma A/S during the 3rd quarter valued at approximately $60,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.